Dicerna Pharmaceuticals (DRNA) Receiving Somewhat Favorable Press Coverage, Accern Reports

Media headlines about Dicerna Pharmaceuticals (NASDAQ:DRNA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.0636639739698 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of Dicerna Pharmaceuticals (DRNA) opened at $10.63 on Friday. The company has a market capitalization of $536.04, a price-to-earnings ratio of -3.10 and a beta of 2.75. Dicerna Pharmaceuticals has a 1-year low of $2.52 and a 1-year high of $11.19.

Several research firms have issued reports on DRNA. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, February 1st. SunTrust Banks assumed coverage on Dicerna Pharmaceuticals in a research note on Monday, February 5th. They set a “buy” rating and a $13.00 price objective for the company. BidaskClub cut Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Evercore ISI assumed coverage on Dicerna Pharmaceuticals in a report on Tuesday, January 16th. They set an “outperform” rating and a $14.00 target price on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. Dicerna Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $10.05.

In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv bought 285,000 shares of the firm’s stock in a transaction dated Monday, December 18th. The shares were bought at an average price of $7.00 per share, for a total transaction of $1,995,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 29.41% of the stock is currently owned by corporate insiders.

WARNING: This report was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://ledgergazette.com/2018/02/17/dicerna-pharmaceuticals-drna-receiving-somewhat-favorable-press-coverage-accern-reports.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply